How the Proactive interview should have gone if yo
Post# of 153886
(Total Views: 529)
Posted On: 12/10/2019 8:52:44 AM
How the Proactive interview should have gone if you communicate effectively:
Christine: "Nader, great to see you!"
Nader: Thanks for having me, Christine!
Christine: "Nader, you wanted to update shareholders on the licensing agreement and the progress in mTNBC"
N: Absolutely. Glad that you ask! We are currently screening x more patients and are expecting to enroll them in y weeks. Also, the CTC readout for my mother-in-law is due in n weeks. If the readout is as positive as the readout of our first patient, we'll take that as a strong confirmation of the ground-breaking potential of our molecule in cancer.
C: Wow, that's great to hear. So, what about financing?
N: We are pleased to report that we have successfully closed negotiations of the promised HIV-licensing deal under the conditions we outlined in September, that is 50% royalties, 90m milestones, 60m commercialisation costs on partner! However, we recently have been aggressively approached by several BP's who are also very interested, so we are currently evaluating all options to get the best possible deal for our shareholders. We will have a CC next week to discuss these developments.
C: You also have brought Dr. Bruce Patterson from IncellDx to educate SH on the science of leronlimab. Dr. Patterson, great to see you! Could you explain to us why leronlimab is working across all those indications?
Patterson: Sure... [...]
C: Well, that's great news! As always, interesting to keep track on your progress! See you next time!
N + P: Thanks for having me!
Christine: "Nader, great to see you!"
Nader: Thanks for having me, Christine!
Christine: "Nader, you wanted to update shareholders on the licensing agreement and the progress in mTNBC"
N: Absolutely. Glad that you ask! We are currently screening x more patients and are expecting to enroll them in y weeks. Also, the CTC readout for my mother-in-law is due in n weeks. If the readout is as positive as the readout of our first patient, we'll take that as a strong confirmation of the ground-breaking potential of our molecule in cancer.
C: Wow, that's great to hear. So, what about financing?
N: We are pleased to report that we have successfully closed negotiations of the promised HIV-licensing deal under the conditions we outlined in September, that is 50% royalties, 90m milestones, 60m commercialisation costs on partner! However, we recently have been aggressively approached by several BP's who are also very interested, so we are currently evaluating all options to get the best possible deal for our shareholders. We will have a CC next week to discuss these developments.
C: You also have brought Dr. Bruce Patterson from IncellDx to educate SH on the science of leronlimab. Dr. Patterson, great to see you! Could you explain to us why leronlimab is working across all those indications?
Patterson: Sure... [...]
C: Well, that's great news! As always, interesting to keep track on your progress! See you next time!
N + P: Thanks for having me!
(5)
(0)